Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA.
Rhea-AI Summary
Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. The session is scheduled for Thursday, September 10, 2026, at 12:45 p.m. ET and will be accessible via the Investors “News & Events” page on the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – MGX
In the Sep 1 session, MGX declined 1.27%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | 2Q26 earnings report | Negative | -0.8% | Net loss widened while collaboration revenue turned negative during the quarter. |
| May 28 | Healthcare conference presentation | Neutral | +3.7% | CEO participation in a fireside chat preceded a 3.7% 24-hour gain. |
| May 11 | 1Q26 earnings report | Neutral | +0.0% | Quarterly results and pipeline updates were followed by no 24-hour price change. |
| Apr 16 | CRISPR research publication | Positive | +0.0% | Publication reported enhanced compact nuclease editing efficiency without a recorded price change. |
| Mar 05 | FY25 earnings report | Positive | -8.1% | Pipeline progress and cash runway updates preceded an 8.07% 24-hour decline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MGX's prior conference announcement was followed by a 3.7% gain, while its recent earnings and research announcements produced mixed or negative reactions.
Key Terms
in vivo genome editing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference, being held in Boston, MA, on Thursday, September 10, 2026, at 12:45 p.m. ET.
The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.
About Metagenomi Therapeutics
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
